SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

Objective

To assess the safety and immunogenicity of live attenuated yellow fever (YF) 17D vaccine in adults receiving systemic corticosteroid therapy.

Methods

All adult travelers on systemic corticosteroid therapy who had received the YF17D vaccine in 24 French vaccination centers were prospectively enrolled and matched with healthy controls (1:2) on age and history of YF17D immunization. Safety was assessed in a self-administered standardized questionnaire within 10 days after immunization. YF-specific neutralizing antibody titers were measured 6 months after vaccination in patients receiving corticosteroids.

Results

Between July 2008 and February 2011, 102 vaccine recipients completed the safety study (34 receiving corticosteroids and 68 controls). The median age was 54.9 years (interquartile range [IQR] 45.1–60.3 years) and 45 participants had a history of previous YF17D immunization. The median time receiving corticosteroid therapy was 10 months (IQR 1–67 months) and the prednisone or equivalent dosage was 7 mg/day (IQR 5–20). Main indications were autoimmune diseases (n = 14), rheumatoid arthritis (n = 9), and upper respiratory tract infections (n = 8). No serious adverse event was reported; however, patients receiving corticosteroids reported more frequent moderate/severe local reactions than controls (12% and 2%, respectively; relative risk 8.0, 95% confidence interval 1.4–45.9). All subjects receiving corticosteroids who were tested (n = 20) had neutralizing antibody titers >10 after vaccination.

Conclusion

After YF17D immunization, moderate/severe local reactions may be more frequent in patients receiving systemic corticosteroid therapy. Immunogenicity seems satisfactory. Large-scale studies are needed to confirm these results.


INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

Yellow fever (YF) 17D vaccine is either strongly recommended or mandatory for people traveling to endemic regions of Africa and Latin America ([1]). Reactions to YF17D vaccine are typically mild ([2, 3]). Headaches, myalgia, low-grade fevers, or other minor symptoms can occur for 5–10 days after immunization. As is the case with other live attenuated vaccines, its administration is contraindicated in patients with immunosuppression because of the potential for severe complications. In patients taking systemic corticosteroids, the amount of systemically absorbed corticosteroids and the duration of administration needed to suppress the immune system are not well defined. US guidelines state that corticosteroid therapy is not usually a contraindication to live attenuated vaccines when administration is either short term (i.e., <14 days) and/or a low to moderate dosage (<20 mg of prednisone or equivalent per day for adults) ([1]). British and French guidelines recommend that for long-term treatments (i.e., <14 days), adults should not be vaccinated above the prednisone or equivalent dosage of 10 mg per day ([4, 5]). Therefore, the recommendation between 10 and 20 mg/day is not consensual.

There are few data in the literature on the safety and immunogenicity of the YF17D vaccine in patients with immunosuppression. Most reports focus on people living with human immunodeficiency virus (HIV) ([6-8]). In patients immunized with theYF17D vaccine after HIV diagnosis, primary and long-term immune responses are impaired compared to healthy individuals. Based on these limited data, there is no evidence of increased incidence of severe adverse reactions in patients infected with HIV with a CD4 cell count ≥350 cells/mm3. However, there is no specific study on the use of YF17D vaccines in people receiving systemic corticosteroids, and national guidelines are mostly based on expert advice. We therefore conducted an observational cohort study to assess the safety and immunogenicity of the YF17D vaccine in adult travelers receiving systemic corticosteroid therapy.

Box 1. Significance & Innovations

  • Based on our data, corticosteroid therapy is not a contraindication to the live attenuated yellow fever 17D vaccine when administration is either short term (i.e., <14 days) and/or a low to moderate dosage (<20 mg of prednisone or equivalent per day for adults); however, the sample size is too small to categorically exclude a low risk of a severe adverse event.
  • Patients should be warned of possible occurrence of moderate/severe local reactions after immunization, even for short-term therapies (i.e., <14 days).
  • Immunogenicity seems satisfactory in patients taking corticosteroids, since all subjects (n = 20) had mounted a yellow fever–specific antibody response by 6 months after immunization.

PATIENTS AND METHODS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

Study design and population

The Amarcor study was conducted between July 2008 and February 2011 in 63 vaccination centers of metropolitan France. Recruitment and followup were based on telephone calls and e-mails to participating centers and patients during the study period. Physicians were invited to prospectively include all adults receiving systemic corticosteroid therapy, with no restrictions on daily dose or duration, who were planning to travel to an area with risk of YF transmission. The study was strictly observational and the decision to vaccinate the patient was taken by the physician alone, according to his or her usual practice. The study protocol was approved by the Ethical Review Committee CPP Ile de France III, Paris, France. For each patient enrolled, the practitioner completed a questionnaire collecting data on the patient's age, sex, place of birth, previous administration of the YF17D vaccine and date of immunization, duration of corticosteroid therapy, daily dose at the start of therapy and at enrollment, as well as underlying conditions. If the physician decided not to vaccinate the patient, reasons were documented in the questionnaire. If the physician administered the vaccine, the patient was invited to participate in the study by signing informed consent and attending prospective followup. After being vaccinated, participants were asked to record, on a self-administered questionnaire supplied by the study, all local (at the injection site) or systemic signs and symptoms occurring in the first 10 days after vaccination. This group of patients constituted the corticosteroids group.

Adverse event (AE) assessment and immunogenicity

Safety data were collected according to a safety toxicity grading scale adapted from the recommendations of the Food and Drug Administration (FDA) ([9]). Both local (pain, tenderness, and erythema/redness) and systemic AEs (fatigue, joint pain/myalgia, headaches, nausea/vomiting, and fever) were documented. The timing and duration of each reaction were collected and the intensity was quoted by the patient as mild, moderate, or severe, based on the impact on daily activities. Serious AEs were defined according to the FDA definition (www.fda.gov) as those causing death, hospitalization, disability/permanent damage, or congenital anomaly/birth defect. These were reported according to a serious AE reporting procedure in the 6 months following immunization.

Each participant in the corticosteroids group was matched to 2 healthy travelers on age (±10 years) and history of previous YF17D vaccination. Safety was assessed in the same way in these participants (reported as controls) within 10 days after vaccination.

Participants in the corticosteroids group were also offered to be tested for YF17D-specific neutralizing antibody titers in the 6 months after vaccination. Neutralizing antibody titers were measured in a centralized laboratory (Cerba, Saint-Ouen l'Aumône, France) using the plaque reduction neutralization test, which is the standard technique for assessing humoral responses to YF17D immunization ([2, 10]). Dilutions ranged from 1:10 to 1:80, and neutralizing antibody titers ≥1:10 were defined as protective.

Statistical methods

Results are expressed as the median (interquartile range [IQR]) for continuous variables and the number (percentage) for categorical variables. The effects of covariates were studied using the Wilcoxon or Fisher's exact test for continuous or categorical variables, respectively. The primary outcome was the reporting of at least one moderate or severe reaction (local or systemic). Relative risks (RRs) and their 95% confidence intervals (95% CIs) were estimated by Miettinen's method for individually matched series ([11]). Statistical analyses were performed using the R 2.11.1 statistical package (R Development Core Team, R Foundation for Statistical Computing [http://www.R-project.org]).

RESULTS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

Participants

Between July 2008 and February 2011, 131 participants were included in 24 vaccination centers (117 vaccinated and 14 not vaccinated). Among the 117 vaccinated participants, 102 (87%) completed followup (34 and 68 in the corticosteroids and controls groups, respectively) (Figure 1) and 20 (59%) in the corticosteroids group completed the immunogenicity assessment. The median age in both groups was 55 years (IQR 45–60 years), 60% of the participants were women, and 77 (75%) were born in metropolitan France. Overall, 45 patients of the 102 participants had been previously vaccinated against YF. This proportion did not differ between the corticosteroids and controls groups, since participants were matched on age and history of previous YF17D vaccination (Table 1). The main indications for corticosteroid therapy were rheumatoid arthritis (n = 9), chronic inflammatory diseases (n = 14), and upper respiratory tract infections (4 acute sinusitis and 4 pharyngitis). The remaining 3 patients were treated for Bell's palsy, dental extraction, and allergy. All patients with upper respiratory tract infections except 1 had been treated with corticosteroids for <7 days (median 3.5 days) with prednisone or equivalent dosages of ≥20 mg/day (median 30 mg/day, IQR 20–60). In the category of long-term therapies (≥15 days, n = 24), all but 1 were treated for either chronic inflammatory disease (n = 14) or rheumatoid arthritis (n = 9). All were receiving prednisone or equivalent of <20 mg/day (21 of 24 were receiving prednisone or equivalent of <10 mg/day). No participants in either the corticosteroids or controls group were treated with other immunosuppressive drugs.

image

Figure 1. Flow chart of study participants.

Download figure to PowerPoint

Table 1. Characteristics of the study participants*
 Corticosteroids (n = 34)Controls (n = 68)Pa
  1. Values are the median (interquartile range) unless otherwise indicated.

  2. a

    By the Wilcoxon or Fisher's exact test.

  3. b

    Graves', Behçet's, Sharp's, or Crohn's disease; hemorrhagic rectocolitis; giant cell arteritis; polymyalgia rheumatica; sarcoidosis; lupus; multiple sclerosis; and systemic sclerosis.

Age at inclusion, years55 (43–59)55 (46–61)0.69
Women, no. (%)22 (65)39 (57)0.53
Region of origin metropolitan France, no. (%)24 (71)53 (80)
Previous yellow fever vaccination, no. (%)15 (44)30 (44)1
Time since last vaccination, years15 (13–18)13 (11–21)0.40
Indication for corticosteroid therapy, no. (%)   
Rheumatoid arthritis9 (27) 
Chronic inflammatory diseasesb14 (41) 
Upper respiratory tract infections8 (24) 
Others3 (9) 
Dose and duration of corticosteroids   
Time receiving corticosteroids, months10 (<1 to 67) 
Long-term (≥15 days) therapies, no. (%)24 (71) 
Prednisone or equivalent dosage, mg/day7 (5–20) 

Safety

No serious AEs were reported. The most frequent AEs reported by the participants were fatigue (n = 23), joint pain/myalgia (n = 23), headaches (n = 19), and pain at the site of vaccine injection (n = 13). Local AEs started a median of 1 day (IQR 0–1 day) after vaccination and lasted for a median of 2 days (IQR 1–3 days). For systemic AEs, the median onset was 3 days (IQR 1–6 days) and the median duration was 2.5 days (IQR 2–7 days). Neither onset nor the duration of local and systemic AEs differed between the corticosteroids and controls groups (P = 0.19 and 0.26, respectively).

The overall report of at least one local or systemic AE did not differ between the groups (RR 1.3, 95% CI 0.9–1.7) (Table 2). However, patients receiving corticosteroids reported more frequent moderate/severe local AEs than controls (12% and 2%, respectively; RR 8.0, 95% CI 1.4–45.9). The frequency of moderate/severe systemic AEs did not differ between the groups (32% and 22%, respectively; RR 1.5, 95% CI 0.9–2.5). Participants vaccinated for the first time did not report significantly more moderate/severe AEs compared to others (3 [6%] of 55 and 1 [2%] of 45 for local reactions, respectively; P = 0.62 and 17 [31%] of 55 and 8 [18%] of 45 for systemic reactions, respectively; P = 0.17). The report rate of moderate/severe local AEs in the corticosteroids group according to duration and daily dose of steroids as compared to the controls group is shown in Figure 2. Both local and systemic AEs were more frequently reported in the subgroup of short-term/high-dose therapies, but the difference was not significant (P = 0.79).

Table 2. Safety of the yellow fever 17D vaccine*
 Corticosteroids (n = 34)Controls (n = 68)RR (95% CI)
  1. Values are the number (percentage) of participants reporting adverse events (AEs) unless otherwise indicated. RR = relative risk; 95% CI = 95% confidence interval.

Local AEs   
Erythema/redness   
Mild34 
Moderate1 
Severe 
Pain   
Mild18 
Moderate21 
Severe1 
Tenderness   
Mild31 
Moderate1 
Severe 
≥1 local AE9 (27)13 (19)1.4 (0.7–2.6)
≥1 moderate/severe local AE4 (12)1 (2)8.0 (1.4–45.9)
Systemic AEs   
Fatigue   
Mild25 
Moderate39 
Severe31 
Joint pain/myalgia   
Mild56 
Moderate29 
Severe10 
Headaches   
Mild28 
Moderate44 
Severe10 
Nausea/vomiting   
Mild04 
Moderate31 
Severe 
≥1 systemic AE15 (44)29 (43)1.0 (0.7–1.6)
≥1 moderate/severe systemic AE11 (32)15 (22)1.5 (0.9–2.5)
image

Figure 2. Percentage of participants who reported at least one moderate/severe local or systemic reaction within 10 days after yellow fever vaccination, according to duration (<15 or ≥15 days) and daily dosage (<10 or ≥10 mg/day) of corticosteroids.

Download figure to PowerPoint

Immunogenicity

Twenty participants from the corticosteroids group were tested for neutralizing antibody titers within a median of 65 days (IQR 55–118 days) after immunization. Their median age was 55 years (IQR 38–60 years), 11 (55%) had a history of previous YF17D immunization, and 17 (85%) had been treated with corticosteroids for >15 days (median 35 months). Indications of corticosteroids were rheumatoid arthritis (n = 9), chronic inflammatory diseases (n = 8), and upper respiratory tract infections (n = 3). All had neutralizing antibody titers ≥1:10. The geometric mean reciprocal neutralizing antibody titer did not differ between participants who had a history of previous YF17D vaccination and those who did not (56.6 UI/ml [95% CI 43.8–73.1] and 51.5 UI/ml [95% CI 33.8–78.4], respectively; P = 0.94).

Patients receiving corticosteroids and not vaccinated

Fourteen patients receiving corticosteroids were not vaccinated. Their median age was 42 years (IQR 35–58 years), 7 were women, 4 were born in metropolitan France, and 4 were born in Sub-Saharan Africa. Five had a history of previous YF17D vaccination. The median time receiving corticosteroids was 42 months (IQR 2–39 months) and the median dosage of prednisone or equivalent was 12.5 mg/day (IQR 5.6–23.8). Nine patients were followed for a chronic inflammatory disease, 3 had solid organ transplants, and 1 had received corticosteroids for laryngitis and another for otalgia. Nine were planning to travel to Sub-Saharan Africa and 5 to South America. In 7 patients (50%), vaccination had been denied because of concomitant administration of an immunosuppressant drug (mycophenolate mofetil, n = 3; azathioprine, n = 2; methotrexate, n = 2; cyclosporin, n = 2; and tacrolimus, n = 1). For 6 other patients, the corticosteroid therapy itself was the main reason for vaccination being denied. In these cases, the dosages of corticosteroids were between 5 and 60 mg/day.

DISCUSSION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

In this observational cohort study of 34 patients receiving systemic corticosteroids and 68 controls, no severe adverse reaction to the YF17D vaccine was observed. However, moderate/severe local AEs were experienced 8 times more frequently in participants receiving corticosteroids. No difference was observed for systemic AEs. By 6 months after vaccination, all participants receiving corticosteroids had neutralizing antibody titers above the protective level.

In healthy adults, reporting of local symptoms after YF17D vaccination varies widely between studies from 3–40% ([3, 12, 13]), which is consistent with our findings in the control group (n = 13 [19%]). To the best of our knowledge, there are no data in the literature on the safety of the YF17D vaccine in people specifically taking corticosteroids. Few data exist for other categories of immunocompromised patients, such as people living with HIV ([6-8, 14-17]) or those treated with immunosuppressive therapies to prevent graft rejection ([18]) or for chronic rheumatic diseases ([19, 20]). Apart from one fatal case of myeloencephalitis following YF vaccination in an adult with HIV infection and low CD4 counts ([21]), no serious AEs following YF vaccination have been observed in these populations. Moreover, local reactions do not seem to be more frequently reported in these retrospective studies; however, AEs had not been prospectively asked about in a standardized questionnaire. Safety of other live or inactivated vaccines in terms of local events is generally satisfactory in patients with impaired immunity, being comparable to that in healthy individuals ([22]). To our knowledge, there was only one recent report of more frequent local transient reactions at the site of the injection in patients treated with immunosuppressant drugs (methotrexate, prednisone, and/or tumor necrosis factor α blockers) for rheumatic diseases, compared to healthy subjects after administration of the MF59-adjuvanted H1N1 virus monovalent influenza vaccine ([23]). On the other hand, some severe systemic AEs have been observed after administering live attenuated vaccines in immunocompromised people caused by disseminated vaccinal disease ([24-27]).

There are very few published data on the immunogenicity of YF17D vaccines in immunosuppressed individuals and none at all on patients taking corticosteroids. Patients infected with HIV respond to the 17D vaccine with lower neutralizing antibody titers, more often demonstrating nonprotective neutralizing antibody titers, and may experience a more rapid decline in neutralizing antibody titers during followup than healthy individuals ([7]). Shorter duration of undetectable plasma HIV RNA and higher plasma HIV RNA levels at immunization have been identified as independent predictors of impaired response ([6]). In rheumatoid arthritis patients receiving infliximab therapy revaccinated by the 17D vaccine, postimmunization neutralizing antibody titers tended to be lower in patients than in controls, but due to the small number of patients, a formal statistical analysis was not performed ([20]).

Lack of other data in the published literature corroborating our findings, as well as intrinsic limitations of our study, must be taken into account when interpreting our results. First, the sample size of our study, as well as those of others, was too small to categorically exclude a low but relevant risk of severe AEs in these immunocompromised populations. Despite the multicenter design and active recruitment based on followup calls and e-mails to participating centers, only 40 vaccinated individuals receiving corticosteroids were identified in 2 years. Some potential participants may have been missed by the investigators. However, before participating in the study, vaccination centers were asked to declare the number of patients receiving corticosteroids vaccinated against YF in the past 12 months. Only 12 (38%) reported at least one vaccination, which is in perfect agreement with the rate of participation (24 [38%] of 63 centers included at least one patient). This suggests that our study sample size reflected the realistic annual rate of YF immunization in patients receiving corticosteroids in France. Second, the robustness of our findings on toxicity must be confirmed in larger cohorts, since only one conflicting report of an AE would have led to non–statistically significant results. Third, as in all nonrandomized observational studies, major local toxicity in people receiving corticosteroids could only be the consequence of an observation bias in this group. Assessment of local and systemic AEs during followup by a blinded clinician in all participants would have been preferable. However, it is likely that such bias would have affected the reporting of both local and systemic AEs, whereas we observed similar reported rates of systemic AEs. Finally, complete evaluation of immunogenicity would have required prevaccination testing of neutralizing antibody titers to identify true seroconversions, as well as additional serologic testing to assess maintenance of antibodies over time. Indeed, the single postvaccination antibody determination does not distinguish a boosted immune response, which presumably occurred in participants who had been previously vaccinated, and a primary immune response in recipients who had never received the vaccine.

Only 40 vaccinated individuals receiving corticosteroids were recruited in 2 years. Since the prevalence of systemic corticosteroid use is estimated to be approximately 1–3% in the general population ([28]), people receiving corticosteroids seem to be underrepresented in the population of travelers to YF-endemic countries. Even if these patients represent a minority of adults undergoing YF17D vaccination, they are likely to increase in the upcoming years due to aging populations and wider use of corticosteroids. Therefore, safety and immunogenicity of YF vaccines are of particular concern in these populations.

Our results are too preliminary to draw general recommendations on the use of YF17D vaccines in people undergoing systemic corticosteroid therapy. However, with a prednisone or equivalent dosage of 10 mg/day, the YF17D vaccine seems to be well tolerated. For higher doses, patients should be warned about possible major local AEs, even for short-term therapies (i.e., <2 weeks). Large-scale studies are needed to confirm these results. In the near future, an inactivated YF vaccine would represent a very valuable alternative in these situations ([29]).

AUTHOR CONTRIBUTIONS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Kernéis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Kernéis, Launay, Ancelle, van der Vliet, Wyplosz, Consigny, Hanslik.

Acquisition of data. Kernéis, Launay, Ancelle, Iordache, Naneix-Laroche, Méchaï, Fehr, Leroy, Issartel, Dunand, Wyplosz.

Analysis and interpretation of data. Kernéis, Launay, Ancelle, van der Vliet, Consigny, Hanslik.

Acknowledgments

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES

The authors would like to thank all of the patients, nurses, and physicians in the investigation centers. The Amarcor Study Group included S. Kernéis (coordinator), T. Ancelle, P.-H. Consigny, J. P. Donne, T. Fehr, C. Goujon, T. Hanslik, O. Launay, D. van der Vliet, and B. Wyplosz.

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. AUTHOR CONTRIBUTIONS
  8. Acknowledgments
  9. REFERENCES
  • 1
    Staples JE, Gershman M, Fischer M.Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep2010;59:127.
  • 2
    Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C.Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.Am J Trop Med Hyg1999;60:104550.
  • 3
    Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al.Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.Am J Trop Med Hyg2002;66:53341.
  • 4
    Vaccinations in the immunocompromised person: guidelines for the patient taking immunosuppressant, steroids and the new biologic therapies. London: The British Society for Rheumatology;2002.
  • 5
    Anon.Le calendrier des vaccinations et les recommandations vaccinales 2012 selon l'avis du Haut Conseil de la santé publique.Bull Epidemiol Hebd2012;14:16188.
  • 6
    Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, et al.Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients.J Acquir Immune Defic Syndr2012;59:3607.
  • 7
    Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al.Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.Clin Infect Dis2009;48:65966.
  • 8
    Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, et al.Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.Trans R Soc Trop Med Hyg2012;106:43744.
  • 9
    US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.2007. URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
  • 10
    Niedrig M, Lademann M, Emmerich P, Lafrenz M.Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.Trop Med Int Health1999;4:86771.
  • 11
    Miettinen OS.Estimation of relative risk from individually matched series.Biometrics1970;26:7586.
  • 12
    Camacho LA, de Aguiar SG, Freire Mda S, Leal Mda L, do Nascimento JP, Iguchi T, et al.Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.Rev Saude Publica2005;39:41320.
  • 13
    Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al.Adverse event reports following yellow fever vaccination.Vaccine2008;26:607782.
  • 14
    Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, et al.Yellow fever vaccine is safe and effective in HIV-infected patients.AIDS2004;18:8257.
  • 15
    Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML.Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.Clin Infect Dis2000;31:E78.
  • 16
    Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S.Vaccination in Brazilian HIV-infected adults: a cross-sectional study.AIDS Patient Care STDS2008;22:6570.
  • 17
    Pistone T, Verdiere CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D.Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.Curr HIV Res2010;8:4616.
  • 18
    Azevedo LS, Lasmar EP, Contieri FL, Boin I, Percegona L, Saber LT, et al.Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study.Transpl Infect Dis2012;14:23741.
  • 19
    Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL.Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases.Rev Soc Bras Med Trop2009;42:237. In Portuguese.
  • 20
    Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L, Oliveira AC, et al.Yellow fever revaccination during infliximab therapy.Arthritis Care Res (Hoboken)2010;62:8968.
  • 21
    Kengsakul K, Sathirapongsasuti K, Punyagupta S.Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.J Med Assoc Thai2002;85:1314.
  • 22
    Pirofski LA, Casadevall A.Use of licensed vaccines for active immunization of the immunocompromised host.Clin Microbiol Rev1998;11:126.
  • 23
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al.Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.Arthritis Care Res (Hoboken)2011;63:10627.
  • 24
    Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al.Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants.Bull World Health Organ2009;87:50511.
  • 25
    Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC, et al.Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression.J Infect Dis2011;204:1893901.
  • 26
    Geiger R, Fink FM, Solder B, Sailer M, Enders G.Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission.J Med Virol1995;47:4424.
  • 27
    Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al.Varicella vaccination in a child with acute lymphoblastic leukaemia.Lancet2007;369:1232.
  • 28
    Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C.Use of oral corticosteroids in the United Kingdom.QJM2000;93:10511.
  • 29
    Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, et al.An inactivated cell-culture vaccine against yellow fever.N Engl J Med2011;364:132633.